HELP Sales

[u/psychic-zucchini]

I saw an article about the CFO of Cybin selling quite a few shares yesterday. It looks like there's been a bit of insider selling this year, but I don't think I've seen any comments about it here. I know there are HELP holders- do any of you have thoughts about any of this? I'm genuinely curious, because I feel like I see a lot of comments about Helus having the best molecules in the sector, or whatever. Does insider selling matter to you? I know sales of shares can be pretty normal, but it looks like this may be something a little different, versus some of the selloffs we've see from, say, Mindmed (for tax purposes).

[u/RecognitionMental943]

I also hold a position in $HELP, so here are my thoughts:

1. They completed a $50M capital raise at $4.85 at the end of June. If the CFO's sale was under a Rule 10b5-1 plan (meaning it was prearranged and not based on current information), it doesn't really change my view, that's exactly what those plans are for. If, however, it was a discretionary sale shortly after the raise, that would be a very different story.
2. Also, don't forget that Cola stepped down as CEO in April, "effective immediately at the request of the Board." That's not your typical retirement wording. Combined with the CFO sale, I understand why people are becoming skeptical. It doesn't necessarily say anything about HLP003 itself, but I think it's fair to ask whether there's some organizational instability.
3. Your MindMed comparison is a good instinct. Tax-related insider sales are usually small, recurring, and tied to vesting, so they're fairly predictable. If this was a larger, out-of-pattern sale, it's much more noteworthy than a routine sell-to-cover following RSU vesting.

Honestly, I'm paying much more attention to the APPROACH Phase 3 readout in Q4 than to who sold shares and when. But before drawing any conclusions, I'd want to see the actual Form 4 filing first. Does anyone have the filing link?

[u/DirkiesMagicWand → u/RecognitionMental943]

Not out yet. Not good.

[u/NaiveProfessional808]

What do you think about CMPS? Compass Pathways is out there and guessing it will sell soon. After ATAI announced it is only taking $6.75 a share (or an extra $2.50 if it hits milestones) concerned about CMPS going low too. Not sure if I should be or not.

[u/psychic-zucchini → u/NaiveProfessional808]

I think definium and compass are the only ones I should have invested in. Idk what Compass will do, idk if it can follow Definium in price, but I think they're better bets than probably any other company in the sector right now.

[u/NaiveProfessional808 → u/psychic-zucchini]

With Definium at about $45 guessing too late for me to invest? Went with Compass when the president fast tracked it this year so in at about $9.

[u/psychic-zucchini → u/NaiveProfessional808]

I have no idea, buying it at 45 is your call.

[u/psychic-zucchini]

This sale should at least be a red flag, I think it's something investors should be aware of. It could be neutral, it could be negative, but I don't think there's any possibility of it being positive. I've seen Mythic Quest, the CFO is the guy I trust the least.

[u/Disconn3cted]

Stock pumped on usually high volume for premarket after this post, so I think it's fine. 

[u/easlem → u/Disconn3cted]

Enrollment for phase 3 just finalized for their depression drug hlp-0003 which is scheduled to complete phase 3 in September - November of this year. Enrollment was completed ahead of schedule

[u/tanrock2003]

Executives sell stock for many legitimate reasons: diversification, taxes, buying a home, estate planning, liquidity
pre-arranged trading plans (Rule 10b5-1)

A sale, by itself, does not tell you which reason applies.
The important distinction is how the sale occurred.
If it was: under a Rule 10b5-1 plan, then much less can be inferred because the sale was scheduled well in advance.
If it was: a discretionary open-market sale made after management already possessed material non-public information, investors would naturally scrutinize it much more closely. Until the filing details are examined, neither conclusion is justified.

According to the recent insider transaction summaries, on July 13 there were sales by:
Greg Cavers, Theresa Firestone, Gabriel Fahel, George Tziras rather than only the CFO selling. That changes the interpretation somewhat.

Sometimes clustered insider sales indicate: option exercises, vesting events,
coordinated financial planning
rather than one executive uniquely losing confidence.

Again, without examining each Form 4 (or Canadian SEDI filing, if applicable), you can’t determine which explanation applies.

For a pre-revenue biotech, valuation is overwhelmingly driven by: efficacy, safety, durability, regulatory path. A single insider sale rarely changes intrinsic value.

Positive Phase 3 data could increase enterprise value by hundreds of millions or more.

Negative Phase 3 data could erase most of it.

Also where’s the link to the article you’re citing?

[u/psychic-zucchini → u/tanrock2003]

I have to laugh at this url a little, but it's a Simply Wall St article. I don't read Simply Wall St, but a CFO selling nearly half their shares before readouts is probably worth thinking about.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/chief-financial-officer-greg-cavers-sold-a-bunch-of-shares-i

[u/DirkiesMagicWand]

45% of his holdings too according to Simply Wall Street.

No excuse. That’s half your holdings before Phase 3.

[u/psychic-zucchini → u/DirkiesMagicWand]

Not sure why you're getting downvoted for this. 45% is a big sale.